NanoFuse Biologics LLC
$193.9K 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pulpdent Corporation
Pulpdent Corporation reported $193,956.22 across General Payments, Research, and Ownership to 159 physicians and teaching hospitals across 161 transactions.
- $194.0K Below-median payer
- All-tracks total
- 161 Above-median volume
- Transactions
- 159 Above-median reach
- Recipients
- +$25.7K
- General Payments vs PY2023
Pulpdent Corporation reported $193,956.22 across all CMS Open Payments tracks (General + Research + Ownership) to 159 physicians and teaching hospitals in Program Year 2024 - ranking #1011 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $79,956.22, averaging $1.2K per recipient.
How Pulpdent Corporation's $194.0K all-tracks total breaks down
Pulpdent Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pulpdent-corporation Pulpdent Corporation
$194.0K · #1011/1,925 · 0.0% industry · PY2024
- TOT $194.0K
- RANK #1011
- SHARE 0.0%
- TXN 161
- RCP 159
- CAT 2
- GEN $80.0K
- ΔGEN +$25.7K
- TOP1 17.5%
- PY 2024
Volume peers
Nearest volume peer: NanoFuse Biologics LLC ($193.9K)
Pulpdent Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pulpdent Corporation's CMS-reported General Payments increased by $25.7K (+47.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PULPDENT CORPORATIONPY2023: PULPDENT CORPORATIONPY2024: PULPDENT CORPORATION. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $54,222.59
- PY2024
- $79,956.22
What the Data Shows for Pulpdent Corporation
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Pulpdent Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $71.9K across 44 transactions, 89.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Pulpdent Corporation's 2-category general-payment breakdown at $71.9K, 89.9% of the reported total.
How Pulpdent Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $71.9K | 44 | 89.9% |
| Food and Beverage | $8.1K | 115 | 10.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $57,350.00 (71.7%) of $79,956.22 in this company's General Payments records across 124 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pulpdent Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Howard Glazer Mr
$14,000.00 across 7 reported transactions
- 2
Todd Snyder Mr
$13,500.00 across 7 reported transactions
- 3
Nathaniel Lawson Mr
$12,000.00 across 12 reported transactions
- 4
Anthony Stefanou Mr
$9,600.00 across 2 reported transactions
- 5
Brittany Warren Bergeron Ms
$8,250.00 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pulpdent Corporation's spend rank (#1011 of 1,925, bottom 48% by spend) and concentration rank (#965 of 1,838, bottom 48% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Bracco Diagnostics Inc. : $410.3K total payments, HHI 1171
- Instylla, Inc. : $144.2K total payments, HHI 1169
- Reprise Biomedical, Inc. : $117.0K total payments, HHI 1168
- DentalEZ Alabama, Inc. : $5.9K total payments, HHI 1168
- Hollister Incorporated : $45.3K total payments, HHI 1167
- Kamada Ltd. : $83.4K total payments, HHI 1166
- Pulpdent Corporation (this company) : $80.0K total payments, HHI 1162
- Optos, Inc. : $585.3K total payments, HHI 1153
- HemoSonics LLC : $100.7K total payments, HHI 1152
- Intercept Pharmaceuticals, Inc. : $2.8M total payments, HHI 1149
- Asensus Surgical, Inc. : $207.1K total payments, HHI 1147
- Alcresta Therapeutics, Inc. : $170.2K total payments, HHI 1141
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pulpdent Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pulpdent Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pulpdent Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Medicem Inc.
$194.1K 94 recipients
Compare payment profiles
Channel Medsystems, Inc.
$194.3K 521 recipients
Compare payment profiles
Carestream Health, Inc.
$193.5K 21 recipients
Compare payment profiles
Sequence LifeScience, Inc
$194.5K 64 recipients
Compare payment profiles
Acorda Therapeutics, Inc
$192.5K 2,002 recipients
Compare payment profiles
Put this to use
Pulpdent Corporation ranks #1011 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Pulpdent Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.